+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dravet Syndrome Market by Offering, Seizure Type, Severity, End-Use - Global Forecast 2025-2030- Product Image
Dravet Syndrome Market by Offering, Seizure Type, Severity, End-Use - Global Forecast 2025-2030- Product Image
Sale

Dravet Syndrome Market by Offering, Seizure Type, Severity, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5977927
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dravet Syndrome Market grew from USD 676.47 million in 2023 to USD 734.04 million in 2024. It is expected to continue growing at a CAGR of 8.70%, reaching USD 1.21 billion by 2030.

Dravet Syndrome is a severe form of epilepsy that manifests in infancy and is associated with prolonged seizures and developmental issues. The market research scope for Dravet Syndrome encompasses the pharmaceutical and biotechnology sectors, focusing on drug development, diagnostics, and patient management solutions. The necessity for robust market research stems from the urgent need to address unmet medical needs, given the syndrome's complexity and impact on patients' quality of life. Applications of market insights include drug development optimization, therapeutic innovations, and enhanced diagnostic tools. The end-use scope primarily targets healthcare providers, research institutions, and pharmaceutical companies.

Current market insights highlight several key factors influencing growth, including increased R&D investments, advancements in genetic research for targeted therapies, and the rising awareness of rare neurological disorders. Recent approval of novel therapies, particularly those centered on cannabinoid-based drugs and genetic modulators, presents substantial market opportunities. To capitalize on these, businesses should focus on strategic partnerships with biotech firms specializing in genetic and epigenetic solutions. However, market growth faces limitations such as high research costs, lengthy clinical trial processes, and stringent regulatory frameworks that could delay product releases.

Challenges persist in accurately diagnosing Dravet Syndrome, as it often requires sophisticated genetic testing. Thus, innovation areas ripe for exploration include the development of more efficient diagnostic assays and personalized medicine approaches tailored to genetic profiles. Embracing digital health technologies that facilitate remote monitoring and data analytics can also pave the way for improved patient care and treatment outcomes. The market is characterized by high competition among emerging biotech firms and established pharmaceutical giants striving to dominate the therapeutic landscape. For sustained business growth, firms should prioritize collaborative research efforts, embrace technological advancements, and maintain a keen focus on patient-centric solutions that align with evolving healthcare needs.

Understanding Market Dynamics in the Dravet Syndrome Market

The Dravet Syndrome Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increase in research and development activities aimed at understanding genetic disorders
    • Rising awareness of rare diseases
    • Supportive regulatory environments for developments in Dravet syndrome therapies and medications
  • Market Restraints
    • High cost of treatment associated with Dravet syndrome
  • Market Opportunities
    • Advancements in genetic therapy for Dravet syndrome therapies and medications
    • Increased funding for rare disease research
  • Market Challenges
    • Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis

Exploring Porter’s Five Forces for the Dravet Syndrome Market

Porter’s Five Forces framework further strengthens the insights of the Dravet Syndrome Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Dravet Syndrome Market

External macro-environmental factors deeply influence the performance of the Dravet Syndrome Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Dravet Syndrome Market

The Dravet Syndrome Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Dravet Syndrome Market

The Dravet Syndrome Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Dravet Syndrome Market

The Dravet Syndrome Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dravet Syndrome Market, highlighting leading vendors and their innovative profiles. These include Biocodex S.A., Bloom Science, Inc., Cyberonics, Inc., Eisai Co., Ltd., Encoded Therapeutics, Epygenix Therapeutics, GW Pharmaceuticals by Jazz Pharmaceuticals plc, Insys Therapeutics, Inc., Longboard Pharmaceuticals, Inc., OPKO Health Inc., Ovid Therapeutics Inc., PTC Therapeutics, Sage Therapeutics, Stoke Therapeutics, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Virpax Pharmaceuticals, Xenon Pharmaceuticals, and Zogenix Inc by UCB.

Market Segmentation & Coverage

This research report categorizes the Dravet Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Offering
    • Diagnosis & Testing Solutions
      • Electroencephalogram
      • Genetic Testing
      • MRI & CT Scans
    • Dietary Therapies
    • Medications
      • Clobazam
      • Stiripentol
      • Valproate
  • Seizure Type
    • Atonic Seizures
    • Myoclonic Seizures
    • Partial seizures
    • Photosensitive Seizures
    • Tonic-Clonic Seizures
  • Severity
    • Mild
    • Moderate
    • Severe
  • End-Use
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in research and development activities aimed at understanding genetic disorders
5.1.1.2. Rising awareness of rare diseases
5.1.1.3. Supportive regulatory environments for developments in Dravet syndrome therapies and medications
5.1.2. Restraints
5.1.2.1. High cost of treatment associated with Dravet syndrome
5.1.3. Opportunities
5.1.3.1. Advancements in genetic therapy for Dravet syndrome therapies and medications
5.1.3.2. Increased funding for rare disease research
5.1.4. Challenges
5.1.4.1. Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis
5.2. Market Segmentation Analysis
5.2.1. Offering: Proliferation of medications to manage & reduce the frequency of seizures
5.2.2. End-Use: Pivotal role of hospitals in treating and managing acute episodes and providing access to specialized equipment
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Dravet Syndrome Market, by Offering
6.1. Introduction
6.2. Diagnosis & Testing Solutions
6.2.1. Electroencephalogram
6.2.2. Genetic Testing
6.2.3. MRI & CT Scans
6.3. Dietary Therapies
6.4. Medications
6.4.1. Clobazam
6.4.2. Stiripentol
6.4.3. Valproate
7. Dravet Syndrome Market, by Seizure Type
7.1. Introduction
7.2. Atonic Seizures
7.3. Myoclonic Seizures
7.4. Partial seizures
7.5. Photosensitive Seizures
7.6. Tonic-Clonic Seizures
8. Dravet Syndrome Market, by Severity
8.1. Introduction
8.2. Mild
8.3. Moderate
8.4. Severe
9. Dravet Syndrome Market, by End-Use
9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics
10. Americas Dravet Syndrome Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Dravet Syndrome Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Dravet Syndrome Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Breakthrough Efficacy of STK-001 in Dravet Syndrome Management: A Comprehensive Analysis of Clinical Trials and Future Prospects
13.3.2. FDA and TGA Approval Ushers Encoded Therapeutics’ Gene Therapy ETX101 into Clinical Trials for Dravet Syndrome
13.3.3. Breakthrough in Gut-Brain Axis Research: Bloom Science's BL-001 Shows Promising Phase 1 Results for Treatment of Dravet Syndrome and ALS
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DRAVET SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. DRAVET SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DRAVET SYNDROME MARKET DYNAMICS
TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ELECTROENCEPHALOGRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MRI & CT SCANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIETARY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ATONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PARTIAL SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PHOTOSENSITIVE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TONIC-CLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 52. CANADA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 53. CANADA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 54. CANADA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 55. CANADA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 57. CANADA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 59. MEXICO DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. CHINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 85. CHINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 86. CHINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 87. CHINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 88. CHINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 89. CHINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. INDIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 91. INDIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 92. INDIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 93. INDIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 94. INDIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 95. INDIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 102. JAPAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 103. JAPAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 104. JAPAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 105. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 107. JAPAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 138. THAILAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 139. THAILAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 141. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 142. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 143. THAILAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 158. DENMARK DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 160. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 161. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 162. DENMARK DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 163. EGYPT DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 164. EGYPT DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 166. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 168. EGYPT DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 170. FINLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 174. FINLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 175. FRANCE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 176. FRANCE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 182. GERMANY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 186. GERMANY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 193. ITALY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 194. ITALY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 195. ITALY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 196. ITALY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 197. ITALY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 198. ITALY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 212. NORWAY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 216. NORWAY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 217. POLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 218. POLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 219. POLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 220. POLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 222. POLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 223. QATAR DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 224. QATAR DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 225. QATAR DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 226. QATAR DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 228. QATAR DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 247. SPAIN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 248. SPAIN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 252. SPAIN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 265. TURKEY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 266. TURKEY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 268. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 269. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 270. TURKEY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 283. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Dravet Syndrome market, which are profiled in this report, include:
  • Biocodex S.A.
  • Bloom Science, Inc.
  • Cyberonics, Inc.
  • Eisai Co., Ltd.
  • Encoded Therapeutics
  • Epygenix Therapeutics
  • GW Pharmaceuticals by Jazz Pharmaceuticals plc
  • Insys Therapeutics, Inc.
  • Longboard Pharmaceuticals, Inc.
  • OPKO Health Inc.
  • Ovid Therapeutics Inc.
  • PTC Therapeutics
  • Sage Therapeutics
  • Stoke Therapeutics
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Virpax Pharmaceuticals
  • Xenon Pharmaceuticals
  • Zogenix Inc by UCB

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 734.04 Million
Forecasted Market Value ( USD ) by 2030 $ 1210 Million
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Dravet Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Dravet Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 135 Pages
  • Global
From
Dravet Syndrome - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Dravet Syndrome - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Dravet Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Dravet Syndrome Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 77 Pages
  • Global
From
Dravet Syndrome Treatment Market 2024-2028 - Product Image

Dravet Syndrome Treatment Market 2024-2028

  • Report
  • 178 Pages
  • Global
From
Dravet Syndrome- Pipeline Insight, 2024 - Product Image

Dravet Syndrome- Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Dravet Syndrome Drug Market

Dravet Syndrome is a rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures. Treatment of Dravet Syndrome typically involves a combination of antiepileptic drugs, dietary therapies, and other therapies. Within the context of Central Nervous System Drugs, the Dravet Syndrome Drug market is a specialized segment of the larger epilepsy drug market. It is composed of drugs that are specifically designed to treat Dravet Syndrome, as well as drugs that are used off-label to treat the condition. The Dravet Syndrome Drug market is composed of both generic and branded drugs. Some of the companies in the market include GW Pharmaceuticals, Zogenix, Eisai, and UCB. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.